Big pharma input for improvements to ClinicalTrials.gov sought from gov't to better match patients with studies
Published December 09, 2013 by OSP
In the 20 months since the White House unveiled its $200 million Big Data R&D initiative, the field has matured and begun to fulfill its potential. Now the government has inked a batch of data-related projects and signed up Eli Lilly, Novartis, and Pfizer as partners. The three Big Pharma companies are tasked with helping to improve ClinicalTrials.gov, in particular by making it more effective at matching patients to studies.